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outcomes that might be triggered by TLR9 or TLR7.
What data are available usually come from studies that
utilize artificial ligands such as CpG oligonucleotides
(for TLR9) or R848 (for TLR7) and may not accurately
reflect the activity of more physiologically relevant
ligands.
These reports leave unanswered a number of critical
questions, including the outcome of combined TLR9,
TLR7 deficiency. In early studies on a mixed back-
ground, mice lacking the TLR adaptor protein, MyD88,
did not produce dsDNA- or Sm-reactive antibodies, sug-
gesting that the combined deficiency would severely de-
crease total autoantibody production, but a contribution
for interleukin-1 family members could not be ruled out
in these studies. It will also be important to extend the
analysis to animal models other than lpr that may be
more or less dependent on either TLR9 or TLR7.
B6.FcgRIIb2/2 mice that inherit the anti-DNA 56R heavy
chain produce high titers of pathogenic DNA autoanti-
bodies at an early age, and IgG forms of those antibodies
are not produced by TLR9-deficient B6.FcgRIIb2/2 56R
knockin mice (Ehlers et al., 2006). Moreover, the Yaa mu-
tation differentially affects BCR transgenic lines that ex-
press DNA and red-blood-cell-reactive receptors (Moll
et al., 2005). Finally, what about non-nucleic-acid-asso-
ciated autoantibodies—are they autoadjuvants? Per-
haps the TLR9 or TLR7 link to DNA- or RNA-associated
autoantigens is just the tip of the iceberg. Additional
PRRs may well contribute to other types of autoanti-
bodies; possibilities include TLR4 and phospholipids
or even non-TLR PRRs reactive with cell-damage- or
death-associated epitopes. Only time will toll!
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399Transforming Growth Factor-b:
Taking Control of T Cells’
Life and Death
To determine how transforming growth factor-b (TGF-
b) controls T cell function, Marie et al. (2006) and Li
et al. (2006a) created mice with T cells lacking TGF-b
signaling receptors. Both report that TGF-b signaling
by T cells is absolutely essential for tolerance and
homeostasis.
Each day, millions of T cells are stimulated to eliminate
harmful microbial invaders without causing secondary
tissue injury or triggering aggressive self-reactive T cells.
Cell-intrinsic and cell-extrinsic regulatory mechanisms
maintain immunologic tolerance and keep the total num-
ber of T cells in homeostatic balance. The hematopoietic
cell-derived cytokine, TGF-b1 has a well-established
role in maintaining this balance. This cytokine controls
T cell activation, proliferation, differentiation, and sur-
vival. Evidence exists that TGF-b1 also plays a role inthe generation, function, and survival of CD4+ regulatory
T (Treg) cells. Therefore, whether the maintenance of
tolerance and homeostasis is a direct effect of TGF-b
on T cells and/or of regulatory T cell control is not known.
In this issue of Immunity, Marie et al. (2006) and Li et al.
(2006a) have each addressed this question by creating
mice with T cells that lack the ability to respond to
TGF-b.
TGF-b1 is a member of a family of cytokines that are
produced by many cell types and regulate the develop-
ment, function, and expansion and/or survival of the
cells of many organ systems. It is generally secreted
as a latent, precursor molecule and converted to its
active form extracellularly. TGF-b signaling is mediated
mainly by two serine-threonine kinase receptors, TGF-
bRI and TGF-bRII, which activate Smad transcription
factors. Crosstalk between Smads and other transcrip-
tional regulators determines functional properties de-
veloped by the cell.
TGF-b has pleotropic positive and negative regulatory
effects on T cells. In general, it inhibits conventional
T cells but supports the homeostasis of both natural
and adaptive Treg subsets. It inhibits T cell proliferation
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400Figure 1. TGF-b Regulation of T Cell Devel-
opment and Function
Studies in mice with a complete deficiency of
TGF-b signaling in T cells revealed that in the
thymus, TGF-b promotes the differentiation
of CD8+ T cells and canonical Va14iNKT cells,
but inhibits the development of natural
CD4+FoxP3+ Treg cells (nTreg). In the periph-
ery, TGF-b signaling inhibits CD4+ T cell acti-
vation, proliferation, and Th1 differentiation
and the ability of CD8+ T cells to become
cytotoxic T lymphocytes (CTL). Others have
also reported that TGF-b inhibits Th2 differ-
entiation and induces CD4+ cells to become
CD25+FoxP3+ adaptive regulatory cells
(aTreg).by blocking interleukin-2 (IL-2) and cyclins, inhibits T
helper 1 (Th1) and Th2 effector cell differentiation, and
downregulates cytotoxic T cell development (Li et al.,
2006b). TGF-b is required for the sustained expression
of the forkhead transcription factor, FoxP3, that con-
trols the function of Treg cells (Marie et al., 2005). With
sufficient IL-2 to overcome its inhibitory effects, TGF-
b can induce peripheral CD8+ T cells to become regula-
tory cells and can induce naive CD4+ T cells to become
CD4+CD25+ Treg cells with functional properties similar
to those of natural CD4+CD25+ Treg cells (Horwitz et al.,
2003).
The pivotal effects of TGF-b1 in immune regulation
were revealed by the studies of mice with genetic dele-
tion of this cytokine. These mice develop a rapidly pro-
gressive multiorgan inflammatory syndrome and die by
3–4 weeks of age (Kulkarni et al., 1993). Because of de-
letion of TGF-b1 in all cells, it was not possible to deter-
mine the specific role of T cells in this syndrome. For
specifically blocking TGF-b signaling in T cells, trans-
genic mice with a dominant-negative TGF-bRII under
a T cell-specific promoter were created. Although spon-
taneous T cell differentiation and autoimmune disease
was observed, the pathology occurred in older mice
and was much less severe than that seen in TGF-b-de-
ficient mice (Gorelik and Flavell, 2000; Lucas et al.,
2000). It is now apparent that TGF-b signaling was only
partially blocked in these mice. This problem has now
been overcome by Marie et al. (2006) and Li et al.
(2006a). Each group has used the cre-loxp system to
delete the TGF-bRII expressed by T cells, resulting in
the total block of TGF-b signaling in T cells.
Both groups report that a complete TGF-b signaling
deficiency in T cells not only recapitulated the multiorgandisease in TGF-b-deficient mice, but also made it more
severe. The mutant mice develop a rapidly progressive,
fatal wasting disease with marked multiorgan infiltration
of leukocytes and demonstrate anti-DNA and other auto-
antibodies to self-proteins. Lymphadenopathy noted
initially is followed by lymphodepletion before death of
the animal.
Mice with a complete deficiency of TGF-b signaling in
T cells have some thymic abnormalities. The generation
of single-positive CD4+ T cells is normal, but Li et al.
(2006a) observed decreased numbers of CD8+ T cells.
Both Marie et al. (2006) and Li et al. (2006a) report de-
creased differentiation of canonical CD1d-dependent
NKT cells in the thymus (Figure 1). This important obser-
vation merits further study. The numbers of CD4+FoxP3+
Treg cells in the thymus are normal or increased, con-
firming that TGF-b is not required for the generation of
natural CD4+CD25+ Treg cells (Marie et al., 2005).
The major pathology in mice with T cells that are not
responsive to TGF-b is in the periphery. Both Marie et al.
(2006) and Li et al. (2006a) find decreased numbers of
Treg cells. These cells are proliferating so that the de-
creased number is the result of accelerated apoptosis.
Both groups report massive activation of peripheral T
cells and documented that this is due to T cell-recep-
tor-specific stimulation and expansion of self-reactive
T cells rather than spontaneous T cell activation. There
are increased numbers of CD4+ and CD8+ IFN-g-pro-
ducing T cells in the periphery. Li et al. (2006a) report
that TGF-b signaling deficiency resulted in upregulation
of T bet expression, which in turn enhanced the differen-
tiation, expansion, and survival of Th1 cell subsets.
Marie et al. (2006) report increased numbers of aberrant,
predominantly CD8+ NKT cells with cytolytic markers.
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the development of CD1d-reactive NKT cells, but also
promotes the development of a highly pathogenic sub-
set on noncanonical NKT cells.
Both groups considered the possibility that uncon-
trolled T cell activity could directly or indirectly be ex-
plained by the decreased numbers of CD4+CD25+FoxP3+
Treg cells. Neither group, however, could produce
evidence to support this possibility. Adoptive-transfer
experiments revealed that CD4+CD25+ Treg cells from
wild-type mice could not rescue TGF-bRII-deficient mice
from the autoimmune disease.
The most compelling evidence that TGF-b indepen-
dently inhibits T cell activation and differentiation with-
out suppressor cells was described by Li et al (2006a).
They crossed TGF-bRII-deficient mice with OT-11
(CD4+ T cell receptor [TCR]-specific for ovalbumin
[OVA] peptide) transgenic mice onto a Rag1-deficient
background to obtain CD4+ T cells that display a
homogenous TCR. These T cells completely lacked
FoxP3 expression so that they could study TGF-b regu-
lation of T cell function without the participation of Treg
cells. The properties of these TGF-bRII-deficient OTII
T cells were much different than those of the polyclonal
TGF-bRII-deficient T cells. Although they developed
an active phenotype in vivo, they failed to differentiate
into Th1 cells or cause autoimmune disease. Thus, with-
outappropriatestimulation, Tcellsdeficient inTGF-bsig-
naling will become activated, but not differentiate into
T effector cells even in the absence of Treg cells.
Studies with TGF-bRII-deficient OT-II mice also
revealed an essential function of TGF-b signaling in
promoting the survival of CD4+ T cells. This finding is
consistent with the ability of TGF-b to enhance antiapop-
totic and decrease death receptor expression. If TGF-b is
essential for maintaining T cell homeostasis, however,
this effect seems paradoxical. One would anticipate that
TGF-b should promote apoptosis to rebalance T cell
numbers that expand after vigorous antigen stimulation.
This result, then, is another example of the bifunctional
effects of TGF-b and probably depends upon the
strength of T cell activation. Strong signaling promotes
positive effects such as FoxP3 induction and survival
elements. In the absence of strong signaling, the sup-
pressive effects of TGF-b predominate and include de-
creased proliferation and acceleration of apoptosis to
restore homeostatic balance.
The need for TGF-b signaling to keep self-reactive T
cells in check provides further evidence against the
concept of immunologic ‘‘ignorance.’’ It had been con-
sidered that potentially aggressive T cells with low-af-
finity receptors for self antigens are not deleted, but
are ‘‘ignorant’’ of their respective target. This concept
was challenged by the finding that transfer of normal
T cells depleted of Treg cells to immunodeficient mice
resulted in inflammatory bowel disease. Of particular
relevance, protection against the disease required
TGF-b produced by the Treg cells (Powrie et al., 1996).Because T cells require biologically active TGF-b to
maintain immunologic tolerance and homeostasis, but
do not generally produce this cytokine themselves,
what cell type is their principal source? Possibilities
include antigen-presenting cells, inflammatory leuko-
cytes, B cells, and Treg cells. The latter are prime candi-
dates. Stimulated, CD4+CD25+, but not CD4+CD252 T
cells produce considerable amounts of latent TGF-b,
some of which is surface bound. A CD252 adaptive Treg
cell subset also binds latent TGF-b to its cell surface.
Oida et al. (2006) have recently reported that CD4+CD25+
Treg cells can convert small amounts of surface bound
latent TGF-b to its active form, and this cytokine is
essential for their suppressive effects. Thus, the ability
of Treg cells to deliver active TGF-b to other T cells by
surface contact establishes them as the primary agent
for TGF-b to maintain tolerance and prevent
autoimmunity.
Finally, subjects with autoimmune diseases such as
systemic lupus erythematosus have impaired lympho-
cyte production of TGF-b and defective regulatory T
cell function. Unfortunately, TGF-b is too toxic to be
administered systemically. However, it is possible to
generate large numbers of Treg cells ex vivo with IL-2
and TGF-b. The transfer of these cells to the patient
may have considerable therapeutic potential not only
to treat autoimmune diseases, but also to prevent allo-
graft rejection.
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